Idecabtagene Vicleucel

Summary

Idecabtagene Vicleucel (CHEMBL4298199) is an approved gene (ATC L01XL07); indicated across 16 conditions including plasma cell myeloma and plasma cell neoplasm.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Gene
• ATC class: L01XL07
• Indications: 16 conditions
• Clinical trials: 14

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4298199
Name	Idecabtagene Vicleucel
Type	Gene
Max phase	4
ATC	L01XL07

Also known as: Abecma, Anti-bcma car t cell, BB-2121, Ide-cel, Idecabtagen vicleucel, Idecabtagene vicleucel, bb2121, IDECABTAGENE VICLEUCEL

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

16 indications (15 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
plasma cell myeloma	4	MONDO:0009693	EFO:0001378
plasma cell neoplasm	4	MONDO:0004959	EFO:0000200
monoclonal gammopathy	4	MONDO:0004960	EFO:0000203
cardiovascular disorder	4	MONDO:0004995	EFO:0000319
immune system disorder	4	MONDO:0005046	EFO:0000540
neoplasm	4	MONDO:0005070	EFO:0000616
vascular disorder	4	MONDO:0005385	EFO:0004264
infectious mononucleosis	4	MONDO:0005810	EFO:0007326
hematologic disorder	4	MONDO:0005570	HP:0001871
hemorrhagic disease	4	MONDO:0002243	MONDO:0002243
vascular hemostatic disease	4	MONDO:0003159	MONDO:0003159
immunoproliferative disorder	4	MONDO:0021334	MONDO:0021334
lymphoproliferative syndrome	4	MONDO:0016537	Orphanet:2442
therapy-related myeloid neoplasm	1	MONDO:0006450	EFO:1000575

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 14.

Phase distribution

Phase	Trials
PHASE2	5
Not specified	4
PHASE3	2
PHASE1	2
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03651128	PHASE3	ACTIVE_NOT_RECRUITING	Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
NCT06045806	PHASE3	ACTIVE_NOT_RECRUITING	A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
NCT03642626	PHASE2	ACTIVE_NOT_RECRUITING	MT2017-45: CAR-T Cell Therapy for Heme Malignancies
NCT05393804	PHASE2	ACTIVE_NOT_RECRUITING	A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
NCT03361748	PHASE2	COMPLETED	Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma
NCT03601078	PHASE2	COMPLETED	An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma
NCT04855136	PHASE1/PHASE2	TERMINATED	Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma
NCT05032820	PHASE2	COMPLETED	Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma
NCT02658929	PHASE1	COMPLETED	Study of bb2121 in Multiple Myeloma
NCT04196491	PHASE1	COMPLETED	A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM)
NCT06154902	Not specified	ACTIVE_NOT_RECRUITING	Real-World Outcomes in Relapsed/Refractory Multiple Myeloma Patients Treated, or Eligible for Treatment, With Idecabtagene Vicleucel
NCT06357754	Not specified	RECRUITING	Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
NCT06698887	Not specified	RECRUITING	A Study to Evaluate the Long-Term Safety of Idecabtagene Vicleucel Treatment in Adults With Newly Diagnosed Multiple Myeloma in Korea
NCT06855121	Not specified	RECRUITING	The Norwegian Immunotherapy in Multiple Myeloma Study

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).